{"id":305058,"date":"2025-12-09T00:00:00","date_gmt":"2025-12-09T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2024-biopharma-type-2-diabetes-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:24:05","modified_gmt":"2026-03-31T10:24:05","slug":"dlsfmd0004-2026-biopharma-type-2-diabetes-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2026-biopharma-type-2-diabetes-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Type 2 Diabetes &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The <span>type 2 diabetes<\/span> (<abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr>) therapy market will expand through 2034, supported by polypharmacy and the growing use of effective branded therapies offering nonglycemic benefits. Although the loss of exclusivity of several key <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> brands (e.g., <abbr data-abbreviation-entity=\"5029\" title=\"dipeptidyl peptidase\">DPP<\/abbr>-4 inhibitors, <abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2 inhibitors, <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products) will exert downward pressure on market sales, the adoption of Eli Lilly\u2019s retatrutide<span> (a first-in-class triple agonist) and orforglipron (an oral nonpeptide <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr>)<\/span>, along with other late-phase emerging therapies, will offset these declines and support the <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> market throughout the forecast period. Significant unmet need remains for disease-modifying therapies that improve long-term patient outcomes and reduce the lifelong management burden faced by <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> patients.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the drivers and constraints in the <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> therapy market, and how will the market evolve over the forecast period?<\/li>\n<li>How has the increasing use of Eli Lilly\u2019s tirzepatide (Mounjaro) affected the prescribing of other <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products, such as Eli Lilly\u2019s dulaglutide (Trulicity) and Novo Nordisk\u2019s SC semaglutide (Ozempic), in the G7 markets?<\/li>\n<li>What impact will the launch of Novo Nordisk\u2019s insulin icodec (Awiqli) have on daily basal insulins and the overall use of insulin analogues?<\/li>\n<li>How will the launch of nonbranded therapies affect the G7 <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> market?<\/li>\n<li>What do key opinion leaders think about late-phase emerging therapies such as Eli Lilly\u2019s retatrutide and Novo Nordisk\u2019s CagriSema?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Geography:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/li>\n<li><strong>Primary research: <\/strong>Country-specific interviews with thought-leading endocrinologists and diabetologists. Survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology: <\/strong>Prevalence of <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> by country with population-specific diagnosed and drug-treated rates.<\/li>\n<li><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> therapies through 2034, segmented by brands \/ generics.<\/li>\n<li><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305058","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305058\/revisions"}],"predecessor-version":[{"id":575266,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305058\/revisions\/575266"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}